100% satisfaction guarantee Immediately available after payment Both online and in PDF No strings attached
logo-home
Principles Of Clinical Pharmacology - Exam 3 Questions And Answers With Verified Solutions (Graded A+) Latest Update 2024/2025. $9.99   Add to cart

Exam (elaborations)

Principles Of Clinical Pharmacology - Exam 3 Questions And Answers With Verified Solutions (Graded A+) Latest Update 2024/2025.

 0 view  0 purchase
  • Course
  • Clinical pharmacology
  • Institution
  • Clinical Pharmacology

Principles Of Clinical Pharmacology - Exam 3 Questions And Answers With Verified Solutions (Graded A+) Latest Update 2024/2025.

Preview 4 out of 79  pages

  • November 14, 2024
  • 79
  • 2024/2025
  • Exam (elaborations)
  • Questions & answers
  • Clinical pharmacology
  • Clinical pharmacology
avatar-seller
Amazingsirpaul
Principles Of Clinical Pharmacology - Exam 3 Questions
And Answers With Verified Solutions (Graded A+) Latest
Update 2024/2025.
Phases of Gastric Acid Secretion - ANSWER 1. Cephalic phase: responses to sight, taste, smell,
thought

2. Gastric phase: mechanical distention of stomach

3. Intestinal phase: digested protein in intestine stimulates gastric acid secretion

Gastric Physiology - ANSWER - M3 receptor - ACh

- H2 receptor - histamine

- CCKB receptor - gastrin



Parietal cell is key; acid secreted into gastric lumen;

Physiology of Gastric Acid Secretion - ANSWER • Parietal cells secrete hydrochloric acid (HCl)
and intrinsic factor (IF)

• Active transport of H+ out of cell via H+/K+ ATPases ("proton

pumps")

• H+ leaves cell; extracellular K+ enters

• Regulators of H+/K+ exchange: *histamine, gastrin, acetylcholine*

Histamine - ANSWER • From mast cells in lamina propria and enterochromaffin-like cells

• Binds to Histamine-2 (H2) receptors on parietal cells

• Stimulates adenyl cyclase and ↑ cAMP which facilitates pumping H+ into lumen by parietal cell
(activates proton pump)

Gastrin and ACh - ANSWER • Gastrin is secreted by G cells in antrum of the stomach

• Acetylcholine (ACh) released by nerve cells in submucosa

• Both bind receptors on parietal cells

• ↑ intracellular calcium activates ATPase (activates proton pump)

• ↑ H+ pumped into lumen

Inhibitors of Acid Secretion: PGE2 and Somatostatin - ANSWER Prostaglandins: *PGE2* ↑
mucosal resistance to injury by:

,• ↑ bicarb secretion

• ↓ gastric acid secretion



D cells secrete *somatostatin*:

• ↓ gastrin release

• ↓ histamine release

• ↓ parietal cell acid secretion

Protectors of the Gastric Mucosa - ANSWER • Gastric mucus

• Prostaglandins

• Bicarbonate

• Repair mechanisms

• Blood flow

Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) - ANSWER Large iatrogenic problem

• > 100,000 pts hospitalized yearly

• 5-10% mortality rate in these pts

• Cause both local injury to the mucosa and systemic effects

NSAIDs - Cox-1 and Cox-2 Inhibition - ANSWER Arachadonic acid —>

- NSAIDs —> *Cox-1* —> *cytoprotective prostaglandins* (platelet aggregation, gastrointestinal mucosal
integrity, renal function)

- NSAIDs and selective Cox-2 inhibitors —> *Cox-2* —> *inflammatory prostaglandins* (pain,
inflammation, mitosis, growth)

Role of NSAIDs in Peptic Ulcer Disease (PUD) - ANSWER Topical (Local) Effects:

- NSAID is weak organic acid

- enters gastric epithelial cell

- ionized and trapped in cell —> cell damage



Systemic Effects:

- ↓ mucosal prostaglandin synthesis

- Possibly also: ↑ adherence of neutrophils to vascular endothelium → free radicals and proteases which
damage mucosa

,Role of H. Pylori in PUD - ANSWER Gram negative bacillus colonizes stomach and duodenum



50% of population worldwide infected with H. Pylori - most never get PUD

Evidence that H. Pylori Causes PUD - ANSWER • 75% of patients with PUD have H. Pylori
infection

• Duodenal ulcers more common among people with H. Pylori

infection than those without infection

• Treating the infection helps ulcer healing

• Ulcers recur less frequently if H. Pylori is eradicated

Mechanism of Ulcer Promotion - ANSWER • Secretes enzymes which disrupt protective mucus
layer

• Presence of bacteria causes neutrophils and other inflammatory cells to gather at site → injury to local
cells

• Produces urease → carbon dioxide and ammonia → toxic to

gastric mucosa

H. Pylori and the Promotion of Gastric Cancer - ANSWER • The bacterium is a carcinogen

• Association with mucosa-associated lymphoid tissue (MALT) lymphomas

• If patient has MALT lymphoma, treatment of H. Pylori usually causes tumor regression

Antibacterial Rx for Patients with Gastric/Duodenal Ulcer and H. Pylori - ANSWER Necessary to
treat H. pylori with antibacterials

- must use at least 2 antibacterial to avoid contributing to resistance



• Clarithromycin

• Amoxicillin

• Bismuth

• Tetracycline

• Metronidazole

• Tinidazole

H. Pylori Treatment - Common Regimens - ANSWER Regimens may contain: bismuth,
clarithromycin, or levofloxacin

, Quadruple Bismuth Therapy:

• Bismuth plus metronidazole plus tetracycline plus PPI for 14 days

• Eradication rate 91%



Triple Clarithromycin Therapy:

• Clarithromycin plus amoxicillin plus PPI bid for 14 days (metronidazole if pcn allergy)

• Lots of Clarithromycin resistance = eradication rate 70-80%



Concomitant Therapy:

• Clarithromycin plus amoxicillin plus nitroimidazole (tinidazole or metronidazole) plus PPI for 14 days

• Needed if high rates of resistance

Other H. Pylori Treatment Regimens - High Resistance - ANSWER Hybrid Therapy:

• Amoxicillin plus PPI for 7 days. Then, amoxicillin plus clarithromycin plus nitroimidazole, plus PPI for 7
days

• Better eradication rates, but very complicated for patients



Levofloxacin-Based Therapies:

• Triple therapy: Levofloxacin plus amoxicillin plus PPI for 10 to 14 days (90% eradication)

• Quadruple therapy: Levofloxacin, omeprazole, nitazoxanide, and doxycycline (LOAD) higher eradication
rates as compared with clarithromycin triple therapy for 10 days (95% eradication)

Choosing Antibiotic Regimen - H. Pylori - ANSWER • Risk factors for macrolide resistance

• Presence of penicillin allergy



• Risk factors for macrolide resistance:

- Prior exposure to macrolide therapy for any reason

- High local clarithromycin resistance rates ≥15 percent or eradication rates with clarithromycin triple
therapy ≤85 percent



If one or more risk factors for macrolide resistance: avoid clarithromycin-based therapy

The benefits of buying summaries with Stuvia:

Guaranteed quality through customer reviews

Guaranteed quality through customer reviews

Stuvia customers have reviewed more than 700,000 summaries. This how you know that you are buying the best documents.

Quick and easy check-out

Quick and easy check-out

You can quickly pay through credit card or Stuvia-credit for the summaries. There is no membership needed.

Focus on what matters

Focus on what matters

Your fellow students write the study notes themselves, which is why the documents are always reliable and up-to-date. This ensures you quickly get to the core!

Frequently asked questions

What do I get when I buy this document?

You get a PDF, available immediately after your purchase. The purchased document is accessible anytime, anywhere and indefinitely through your profile.

Satisfaction guarantee: how does it work?

Our satisfaction guarantee ensures that you always find a study document that suits you well. You fill out a form, and our customer service team takes care of the rest.

Who am I buying these notes from?

Stuvia is a marketplace, so you are not buying this document from us, but from seller Amazingsirpaul. Stuvia facilitates payment to the seller.

Will I be stuck with a subscription?

No, you only buy these notes for $9.99. You're not tied to anything after your purchase.

Can Stuvia be trusted?

4.6 stars on Google & Trustpilot (+1000 reviews)

77858 documents were sold in the last 30 days

Founded in 2010, the go-to place to buy study notes for 14 years now

Start selling
$9.99
  • (0)
  Add to cart